Balyasny Asset Management
BBNX

Balyasny Asset Management’s Beta Bionics BBNX Stock Holding History

Balyasny Asset Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
855,682
+237,767
+38% +$2.83M 0.02% 928
2026
Q1 		$6.19M Buy
617,915
+532,942
+627% +$7.88M 0.01% 1270
2025
Q4 		$2.59M Buy
84,973
+82,458
+3,279% +$2.2M ﹤0.01% 1741
2025
Q3 		$50K Buy
2,515
+2,424
+2,664% +$42.6K ﹤0.01% 2820
2025
Q2 		$1.32K Sell
91
-49,787
-100% -$705K ﹤0.01% 2733
2025
Q1 		$611K Buy
+49,878
New +$930K ﹤0.01% 2201

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Balyasny Asset Management's BBNX Position: Q2 2026 in Review

Balyasny Asset Management increased its Beta Bionics (BBNX) stake by 38% in Q2 2026, buying an estimated $2.83M and bringing the position to 855,682 shares worth $13.4M. The position accounts for 0.02% of the portfolio, ranked #928.

Balyasny Asset Management first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Balyasny Asset Management held 855,682 shares of Beta Bionics worth $13.4M as of Q2 2026.
  • Balyasny Asset Management bought 237,767 Beta Bionics shares in Q2 2026, an estimated $2.83M.
  • Beta Bionics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #928 holding.
  • Balyasny Asset Management first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.